Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Buys 19,748 Shares

Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc purchased 19,748 shares of the company’s stock in a transaction on Friday, January 17th. The shares were purchased at an average cost of $13.87 per share, for a total transaction of $273,904.76. Following the completion of the transaction, the director now directly owns 15,720,161 shares of the company’s stock, valued at approximately $218,038,633.07. This represents a 0.13 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Wednesday, January 15th, Ecor1 Capital, Llc bought 39,029 shares of Zymeworks stock. The stock was purchased at an average cost of $14.01 per share, for a total transaction of $546,796.29.
• On Monday, January 13th, Ecor1 Capital, Llc purchased 74,125 shares of Zymeworks stock. The shares were acquired at an average price of $13.39 per share, with a total value of $992,533.75.
• On Friday, January 10th, Ecor1 Capital, Llc acquired 204,098 shares of Zymeworks stock. The stock was acquired at an average price of $13.13 per share, for a total transaction of $2,679,806.74.
• On Wednesday, January 8th, Ecor1 Capital, Llc bought 21,021 shares of Zymeworks stock. The shares were acquired at an average price of $14.07 per share, with a total value of $295,765.47.
• On Thursday, January 2nd, Ecor1 Capital, Llc purchased 157,880 shares of Zymeworks stock. The shares were acquired at an average cost of $14.78 per share, with a total value of $2,333,466.40.
• On Monday, December 30th, Ecor1 Capital, Llc acquired 58,988 shares of Zymeworks stock. The shares were bought at an average cost of $14.47 per share, with a total value of $853,556.36.
• On Tuesday, December 24th, Ecor1 Capital, Llc bought 11,958 shares of Zymeworks stock. The shares were bought at an average price of $14.12 per share, with a total value of $168,846.96.
• On Thursday, December 26th, Ecor1 Capital, Llc purchased 16,692 shares of Zymeworks stock. The stock was bought at an average price of $14.38 per share, for a total transaction of $240,030.96.

Zymeworks Trading Up 1.0 %

NYSE ZYME opened at $14.82 on Friday. Zymeworks Inc. has a 12 month low of $7.97 and a 12 month high of $17.70. The firm has a market capitalization of $1.02 billion, a PE ratio of -9.88 and a beta of 1.10. The business’s 50-day moving average price is $14.09 and its two-hundred day moving average price is $12.78.

Zymeworks (NYSE:ZYME) last announced its earnings results on Thursday, October 31st. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.01. Zymeworks had a negative return on equity of 23.00% and a negative net margin of 182.75%. The business had revenue of $16.00 million for the quarter, compared to analysts’ expectations of $17.90 million. During the same period in the prior year, the business posted ($0.41) earnings per share. The firm’s revenue was down 3.1% on a year-over-year basis. As a group, analysts forecast that Zymeworks Inc. will post -1.39 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Stifel Nicolaus upped their target price on Zymeworks from $21.00 to $28.00 and gave the company a “buy” rating in a research report on Monday, October 28th. Wells Fargo & Company raised their price objective on Zymeworks from $12.00 to $14.00 and gave the stock an “equal weight” rating in a research note on Thursday, December 19th. Leerink Partnrs upgraded Zymeworks from a “hold” rating to a “strong-buy” rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. upgraded shares of Zymeworks from a “neutral” rating to an “overweight” rating and set a $18.00 price objective for the company in a research report on Monday, December 16th. Finally, Citigroup increased their price objective on shares of Zymeworks from $16.00 to $18.00 and gave the company a “buy” rating in a research note on Monday, November 4th. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $19.17.

Hedge Funds Weigh In On Zymeworks

Hedge funds have recently bought and sold shares of the company. FMR LLC boosted its position in Zymeworks by 84.2% during the third quarter. FMR LLC now owns 3,336 shares of the company’s stock valued at $42,000 after acquiring an additional 1,525 shares during the last quarter. DekaBank Deutsche Girozentrale acquired a new position in shares of Zymeworks in the 3rd quarter valued at about $47,000. nVerses Capital LLC acquired a new position in shares of Zymeworks in the 3rd quarter valued at about $79,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Zymeworks by 64.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,665 shares of the company’s stock valued at $171,000 after purchasing an additional 5,359 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in Zymeworks during the second quarter worth approximately $121,000. Institutional investors own 92.89% of the company’s stock.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.